PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with adenocarcinoma (a type of prostate cancer) confirmed by biopsy
- You have had prior surgery (prostatectomy) or radiation therapy for your original prostate cancer
- Cancer has spread to a small number of sites (10 or fewer spots total, no brain or liver involvement) that light up on a PSMA PET scan
- Your cancer is hormone-sensitive (not yet resistant to hormone therapy) and shows early signs of spread (either new metastases or recurrence)
- You have acceptable blood cell counts, liver, and kidney function; no severe dry mouth condition
- You can start treatment within 28 days and have a life expectancy of at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This study uses a special scan (PSMA PET/CT) to see how well a new type of hormone therapy is working in men whose prostate cancer has spread to other parts of the body. The goal is to find out if the scan can help doctors track the cancer's response to treatment over time.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
Hear when a new Stage IVB Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.